Research programme: 212Pb targeted alpha therapies - Orano Med/Sanofi
Alternative Names: Lead-212 targeted alpha therapies - Orano Med/SanofiLatest Information Update: 19 Nov 2024
Price :
$50 *
At a glance
- Originator Orano Med; Sanofi
- Class Antineoplastics; Radioisotopes; Radiopharmaceuticals
- Mechanism of Action Ionising radiation emitters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer